Jon Ellis and Simon Vanstone, PhD, go behind the headlines to explore the latest M&A activity and what tariffs and funding changes could mean for mRNA and beyond.

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

Sanofi SNY announced that the FDA has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, ...

Disappointing results for iluzanebart come shortly after Vigil Neuroscience struck a buy-out deal with Sanofi, but analysts ...

A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the ...

Tufan Erginbilgiç's four pillars involved showing employees the extent of Rolls-Royce's issues, then giving them a say in ...

Morgan Stanley analyst Sarita Kapila resumed coverage of Sanofi (NASDAQ:SNY), assigning an Equal Weight rating and setting a $56 price target.

A French pharmaceutical giant is acquiring a biotech and its rare immunology disease treatment which is already approved in ...

Though they are both multiple myeloma drugs with the same mechanism of action, Sanofi’s Sarclisa has had difficulty competing ...

Here are the five things you need to know, including Lyra's good news, Sanofi's acquisition, Mass. biotech jobs, inside Market Basket's board, AI, and hiring entry-level jobs.

Sanofi SA has exercised its option to exclusively license Nurix Therapeutics Inc.’s STAT6 program, including the drug development candidate NX-3911, an oral, highly selective STAT6 degrader.

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...